A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Eli Lilly's Zepbound and Novo Nordisk's Wegovy, both priced at over $1,000 a month, have faced resistance from employers due to their high up-front costs. However, drugmakers argue that covering these ...

Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

FRANKFURT (Reuters) - Healthcare executives and investors expect an uptick in initial public offerings and corporate ...

There’s no hard-and-fast rule for how long it’s safe to stay on Ozempic for weight loss. Novo Nordisk-sponsored studies lasting up to two years show that semaglutide is safe.

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...